Johnson & Johnson (JNJ: Aaa/AAA neg)



The FT give a good summary of the growth in Litigation Finance driven by Private Equity backers and its impact on the risk for large corporations.

JNJ's latest class action lawsuit may see the company paying $6.5bn in present value to resolve 10s of thousands of claims alleging cancer caused by its talc products.

{https://www.ft.com/content/abd5bf98-378f-4322-b930-68c9b410e783}